Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Sarcoma 5Rhabdomyosarcoma 4Osteosarcoma 3Carcinoma, Non-Small-Cell Lung 3Sarcoma, Synovial 2Prostatic Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Liposarcoma 2Hemangiosarcoma 2Fibrosarcoma 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Adrenocortical Carcinoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Uveal Melanoma 1Unspecified Childhood Solid Tumor, Protocol Specific 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Retinoblastoma 1Pinealoma 1Paraganglioma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms 1Mesothelioma, Malignant 1Malignant mesenchymal tumor 1

Interventions

Trastuzumab 12Paclitaxel 10Taxes 9Doxorubicin 7Cyclophosphamide 7Docetaxel 6Bevacizumab 6Lapatinib 5Filgrastim 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5Vorinostat 4tipifarnib 3pegfilgrastim 3cediranib 3Peripheral Blood Stem Cell Transplantation 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Carboplatin 3Capecitabine 3veliparib 2ixabepilone 2entinostat 2alvocidib 2Tamoxifen 2Radiotherapy 2Neoadjuvant Therapy 2MK 2206 2Interleukin-12 Subunit p35 2Interleukin-12 2Immunoenzyme Techniques 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Breast Neoplasms, Male × cixutumumab × Clear all
NCT00699491 2018-06-13

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
48 enrolled 14 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡